Pharmacokinetics, Efficacy and Safety of Twice Daily Dosing Regimen of Hydroxycarbamide Dispersible Tablets in Children With Sickle Cell Disease
NCT06578507
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
50
Enrollment
INDUSTRY
Sponsor class
Conditions
Sickle Cell Disease
Interventions
DRUG:
Hydroxycarbamid
Sponsor
Theravia